Call for Applications Now Open for New Stand Up To Cancer-Dutch Cancer Society Dream Team Translational Cancer Research Grant
December 12, 2013
Up to 6 million-euro grant available; application deadline is April 1, 2014
PHILADELPHIA — The American Association for Cancer Research (AACR) is now accepting applications for a Sta Op Tegen Kanker (“Stand Up To Cancer” in Dutch) Dream Team Translational Cancer Research Grant. This grant opportunity will offer up to 6 million euros (U.S. $8.25 million, at the current conversion rate) in research funding and is provided by Stand Up To Cancer (SU2C) and KWF Kankerbestrijding (the Dutch Cancer Society).
The grant provides four years of funding for a translational cancer research project that will address critical problems in patient care and deliver near-term patient benefit through investigation by a multidisciplinary, multi-institutional team of expert investigators. Research projects must be designed to accelerate the application of new preventive, diagnostic, or therapeutic agents to the clinic, and may focus on particular organ sites or on specialized research areas.
Proposals for the Sta Op Tegen Kanker Dream Team Translational Cancer Research Grant should describe plans indicating how the work will be translated into the clinic. To maximize creativity, innovation, and collaboration, the projects should also span multiple disciplines and use modern biological tools to address research questions in a coordinated way.
The leader of each project must be from a research institute located in the Netherlands. Co-leaders can be from research institutes in any country. Each project must include at least two research institutes located in the Netherlands and at least one research institute outside the Netherlands. At least 50 percent of the grant funds must be allocated to research conducted in the Netherlands.
Since the launch of SU2C in 2008, the AACR has played an integral role as SU2C’s scientific partner by providing scientific leadership, expert peer review, and grants administration. To that end, the AACR will work closely with the Dutch Cancer Society on this project. A SU2C-KWF Joint Scientific Advisory Committee will conduct a unique, rapid, and rigorous evaluation of the applications via a multistep scientific review process and make recommendations on the final grant recipients. Arnold J. Levine, Ph.D., professor at the Institute for Advanced Study in Princeton, N.J. and at the Cancer Institute of New Jersey in New Brunswick, N.J., will serve as chairperson of the committee. He will be joined by three distinguished scientists—two from research institutes in the Netherlands, and one from a research institute outside the Netherlands.
- Proposals for Sta Op Tegen Kanker Dream Team Translational Cancer Research projects are due by April 1, 2014, via proposalCENTRAL.
- For general information on eligibility criteria, the application process, and other details about this Dream Team grant, visit www.AACR.org/SU2Cfunding. Inquiries may be directed to the Scientific Review and Grants Administration Department at 267-765-1049 or email@example.com.
The Sta Op Tegen Kanker Dream Team Translational Cancer Research Grant is scheduled to be announced in the fall of 2014.
This grant is supported with money raised in connection with the Dutch versions of SU2C’s televised fundraising events, broadcast in the Netherlands in cooperation with the Dutch Cancer Society.